| |
January 9-10, 2024 | San Francisco, CA January 16-18, 2024 | Virtual Driving the Future of Companion Diagnostics: Technology, Translational Medicine, & Commercialization in the Next Decade. Register today and Save $450!
|
|
Today’s Big NewsNov 1, 2023 |
| By Annalee Armstrong If you’ve been living under a rock for the past several years, you probably still know what a GLP-1 inhibitor is—at least by brand name. But the 33,000 attendees at the European Society for Medical Oncology would like to remind you that there’s plenty of breakthroughs in cancer worthy of the same kind of fanfare. |
|
|
|
By Max Bayer FDA advisers appear satisfied with CRISPR Therapeutics and Vertex Pharmaceuticals’ assessment of potential off-target effects from their CRISPR-based gene therapy exa-cel, quelling the top concern from the FDA as an approval deadline nears. |
By Gabrielle Masson With a confirmatory trial for Sarepta’s Duchenne muscular dystrophy trial ending in failure, Pfizer’s chief scientist says the pharma giant’s gene therapy is now “the main game in town.” |
Sponsored by Medidata The clinical trial landscape has seen a seismic shift in recent years, spurred by technology-driven data collection. Yet there are some opportunities… |
|
Convert more DNA into sequenceable library for enhanced sensitivity — particularly with cfDNA samples and ctDNA detection. Prepare highly complex libraries in under 2 hours from as little as 500 pg. Explore the data.
|
|
By James Waldron GSK has dropped its in-house STING agonist only a day after a similar drug the British Big Pharma reserved the rights was finally lifted from clinical hold limbo. |
By James Waldron Despite dropping its multiple myeloma CAR-T only five months ago, Cellectis has secured over $100 million in upfront cash and equity investment from AstraZeneca for a 10-candidate deal. |
By Max Bayer Bioluminescence is rocketing out of stealth, looking to warm a frigid funding environment with the embrace of fresh funding. |
By Annalee Armstrong Sanofi is making an initial $30 million investment in MeiraGTx to gain a first peek at data from the biotech’s riboswitch platform, all for a chance to someday brew up some new deals. |
By James Waldron Tonix Pharmaceuticals’ pipeline has taken another hit as the biotech drops a major depression disorder therapy after the drug flamed out of a phase 2 trial. |
By Gabrielle Masson In a year riddled with obstacles and adverse events, Mersana Therapeutics finally has some good news: The FDA has lifted a clinical hold on a phase 1 trial for the antibody-drug conjugate XMT-2056. |
By Gabrielle Masson C4 Therapeutics is discontinuing one of its cancer assets after a phase 1/2 trial proved the drug ineffective. |
By Joseph Keenan NASA and Defender Pharmaceuticals will test an anti-nausea gel in two clinical trials, recruiting astronauts to undergo motion simulation exercises to test sensorimotor performance. |
By Angus Liu Aside from Pfizer's declining COVID-19 sales, GSK is giving the New York drugmaker another reason to worry. In the first round of their RSV vaccine showdown, GSK's Arexvy pulled down $860 million, more than doubling the haul from Pfizer's Abrysvo. |
By Conor Hale The Biden administration is launching a federal outfit to evaluate the safety of AI, and to address its impact in healthcare, R&D and the broader societal concerns that have recently come to the fore. |
By Kevin Dunleavy The FDA has approved Amgen’s biosimilar version of Johnson & Johnson’s autoimmune standout Stelara. But the new product will not launch until 2025 because of a settlement the companies made earlier this year, which delayed the launch in exchange for J&J dropping a patent infringement lawsuit. |
By Noah Tong Third-party administrator Yuzu Health says it can help insurance companies and brokers provide small businesses up to 40% in savings. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of “Podnosis,” we explore Blue Shield of California's plan to transform its pharmacy model. This includes a shift away from the traditional PBM relationship in favor of forming partnerships with five companies: Amazon Pharmacy, Abarca, Mark Cuban Cost Plus Drugs Company, CVS Caremark, and Prime Therapeutics. |
|
|---|
|
|
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| WhitepaperCell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
| WhitepaperUncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
| |
|
